IG
CPRX

ING Group’s Catalyst Pharmaceutical CPRX Stock Holding History

ING Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-140,911
Closed -$271K – 736
2018
Q4 		$271K Buy
+140,911
New +$403K 0.01% 610

Other funds holding CPRX

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

ING Group's CPRX Position: Q1 2019 in Review

ING Group sold out of Catalyst Pharmaceutical (CPRX) in Q1 2019, closing a stake of 140,911 shares — an estimated $271K sold.

ING Group first reported a position in CPRX in Q4 2018 and held it in 1 quarter. The position peaked at $271K in Q4 2018. 88 funds tracked by Wall St. Rank hold CPRX as of Q1 2019.

  • ING Group reported no remaining Catalyst Pharmaceutical position as of Q1 2019 after selling out during the quarter.
  • ING Group sold 140,911 Catalyst Pharmaceutical shares in Q1 2019, an estimated $271K.
  • ING Group first reported a position in Catalyst Pharmaceutical in Q4 2018 and held it in 1 quarter.
  • ING Group's Catalyst Pharmaceutical position peaked at $271K in Q4 2018.
  • 88 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2019.

Based on ING Group's 13F filing for Q1 2019, filed 13 May 2019.